INTRODUCTION AND OBJECTIVES: Prostaglandin E2 (PGE2) has been shown to play a central role in not only inflammation but also cell proliferation as an antiapoptotic molecule. Accordingly, inhibition of PGE2 is considered a possible anticancer strategy. Meanwhile, PGE2 exerts its effects via G-protein-coupled receptors (GPCRs), including PGE2 receptor 2 (EP2) and EP4. Nonetheless, it remains to be resolved whether and how GPCR signaling is involved in bladder cancer (BC) initiation and outgrowth. The present study aimed to investigate the functional role of prostaglandin receptors, as well as the efficacy of a selective cyclooxygenase-2 inhibitor celecoxib, in urothelial tumorigenesis and cancer progression.
METHODS: We performed immunohistochemistry in bladder cancer tissue microarrays consisting of 129 urothelial neoplasms and separate 37 muscle-invasive BCs from patients who subsequently received cisplatin-based neoadjuvant chemotherapy, in vitro transformation assay in a normal urothelial SVHUC line, and western blot/ RTPCR/cell growth assays in BC lines.
RESULTS: EP2/EP4 expression was elevated in BCs compared with non-neoplastic urothelial tissues and in BCs from those who were resistant to neoadjuvant chemotherapy. Strong positivity of EP2/EP4 in non-muscle-invasive tumors or positivity of EP2/EP4 in muscle-invasive tumors strongly correlated with disease progression or disease-specific mortality, respectively. In SVHUC cells, exposure to a chemical carcinogen 3-methylcholanthrene (MCA) considerably increased and decreased the expression of EP2/EP4 and PTEN, respectively. Treatment with selective EP2/EP4 antagonist or celecoxib also resulted in prevention in MCA-induced neoplastic transformation of SVHUC cells. In BC lines, EP2/EP4 antagonists and celecoxib effectively inhibited cell viability and migration, as well as augmented PTEN expression. Furthermore, these drugs enhanced the cytotoxic activity of cisplatin in BC cells. EP2/EP4 and PTEN were also elevated and reduced, respectively, in cisplatin-resistant BC sublines.
CONCLUSIONS: EP2 and EP4 play an important role in inducing urothelial tumorigenesis, bladder tumor progression, and chemoresisance in BC cells, via downregulating PTEN expression. Thus, EP2/EP4 inactivation, using available inhibitors, has the potential of being not only a chemopreventive and therapeutic option for urothelial cancer but also a means of chemosensitization particularly in patients with EP2/EP4-positive tumors.
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MP54-09 TM4SF1 IS A NOVEL BIOMARKER FOR HUMAN MUSCLE INVASIVE BLADDER CANCER (MIBC)
Rui Cao*, Gang Wang, Kaiyu Qian, Liang Chen, Yu Xiao, Xinghuan Wang, Wuhan, China, People's Republic of INTRODUCTION AND OBJECTIVES: BCa is a heterogeneous disease: non-muscle-invasive bladder cancer (NMIBC) that usually recur but rarely process, and muscle-invasive bladder cancer (MIBC) that progress quickly. Recent studies identify numerous clinical variables and molecular biomarkers, such as chromosomal markers, genetic variations or epigenetic alterations for prediction of its occurrence and recurrence. However, effective biomarkers to distinguish MIBC from NMIBC are urgently needed. Transmembrane-4-L-Six-Family-1 (TM4SF1) is a member of L6 family, which functions as signal transducer to regulate cell development, growth and motility. The aim of the study is to investigate the TM4SF1 as the specific biomarker of MIBC via bioinformatics analysis.
METHODS: Through mining the big data from GEO and TCGA, a specific MIBC differentially expressed gene (DEG) called TM4SF1 was screened by R and validated by oncomine database, etc. Then qRT-PCR, immunofluorescence and immunohistochemistry analysis were used to detect the transcription and translation level of TM4SF1 in bladder tissues. Clinical correlation was measured by connecting the expression of TM4SF1 with patients 0 information. Moreover, TM4SF1 knockdown and overexpression BCa cell model was established by gene regulation. Then flow cytometry, CCK-8 assay, western blot, etc. were used to detect cell cycle distribution, cell growth and related protein expression in vitro. Furthermore, the xenograft model was used to measure the tumor growth of BCa cells transplantation in vivo.
RESULTS: Our results suggested that TM4SF1 was strongly upregulated in MIBC tissues, corroborated with transcriptome analysis. Moreover, tissue microarray (TMA) showed significant correlations between TM4SF1 with T stage, TNM stage, lymph node metastasis status and survival rate of MIBC patient. Furthermore, in vitro and in vivo studies suggested that proliferation of human bladder cancer (BCa) cells was significantly suppressed by downregulated TM4SF1. Functionally, reduction of TM4SF1 could induce cell cycle arrest and apoptosis possibly via upregulation of reactive oxygen species (ROS) in the BCa cells. Interestingly, these observations were scavenged by treatment of GW9662 (antagonist of PPARg) and resveratrol (activator of SIRT1), respectively. CONCLUSIONS: We have first shown tumor promoting effect of TM4SF1 on MIBC. TM4SF1 could be a biomarker to predict the survival rate of MIBC patients and malignancy of the tumor. And our study suggest that the regulation of ROS metabolism and cell cycle for TM4SF1 in BCa cells was mediated by PPARg-SIRT1 feedback loop. To evaluate the hypothesis that muscarinic acetylcholine receptors may play a role in bladder cancer as well as in other tumor types, we investigated their expression in bladder tumor specimens.
METHODS: Human bladder cancer 5637, T24 and HT1197 cell lines (grade 2, 3, 4; respectively) were purchased from Cell Lines Service (CLS Eppelheim, Germany) and ICLC (ICLC, Genova, Italy), respectively. Bladder cancer tissue was obtained from a total of 16 patients underwent to surgical treatment (8 with non-muscle invasive low and 8 with high grade of TCC). Four urothelial samples, obtained from patients underwent bladder biopsy for diseases other than bladder tumor (all selected cases suffering from ureteral lithiasis) were used as controls. M2 receptor expression has been measured by quantitative PCR, immunofluorescence and immunohistochemistry. Arecaidine (M2 receptor agonist)-treated and control cells were compared for changes in the growth pattern, survival and migration properties.
RESULTS: All examined samples expressed the M1, M2 and M3 receptor subtypes. We also found that the level of M2 transcripts, but not those of M1 or M3, significantly increased with the tumor histologic grade. In view of these results, we proceeded to investigate whether the M2 agonist Arecaidine had any effect on in vitro cell growth and migration of T24 cells, a bladder tumor cell line expressing the muscarinic receptors, including the M2 subtype. We observed that Arecaidine significantly reduced T24 and 5637 cell proliferation and migration in a concentration dependent manner. The silencing of M2 receptor by siRNA in T24 and 5637 cell lines showed the inability of Arecaidine (100 mM) to inhibit cell proliferation after 48 hours, whereas the use of M1 and M3 antagonists in T24 appeared not to counteract the Arecaidine effect, suggesting that the inhibition of cell proliferation was directly dependent on M2 receptor activation.
CONCLUSIONS: For the first time we show that M2 is upregulated in high grade urothelial bladder cancer specimens and that its agonistic stimulation affect both in vitro proliferation and migration of urothelial cancer cell line. We believe that our data could help to clarify the role of the M2 muscarinic receptors in urothelial bladder cancer. These data suggest that M2 muscarinic receptors may play a relevant role in bladder cancer and represent a new attractive therapeutic target. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e715
